AstraZeneca Merck & Co.\'s PARP inhibitor Lynparza gains EU approval in breast cancer httpswww.firstwordpharma.comnode1634317Â $AZN $MRK

AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer https://www.firstwordpharma.com/node/1634317  $AZN $MRK

06:03 EDT 10 Apr 2019 | FirstWord Pharma

AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer https://www.firstwordpharma.com/node/1634317  $AZN $MRK

More From BioPortfolio on "AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer https://www.firstwordpharma.com/node/1634317  $AZN $MRK"